TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Abbott Laboratories ( (ABT) ) is now available.
On December 12, 2025, Abbott Laboratories announced the appointment of Nita Ahuja, M.D., to its Board of Directors, expanding the board from twelve to thirteen members. This strategic move is part of Abbott’s ongoing efforts to strengthen its leadership and enhance its governance structure, potentially impacting its operational strategies and stakeholder engagement.
The most recent analyst rating on (ABT) stock is a Buy with a $155.00 price target. To see the full list of analyst forecasts on Abbott Laboratories stock, see the ABT Stock Forecast page.
Spark’s Take on ABT Stock
According to Spark, TipRanks’ AI Analyst, ABT is a Outperform.
Abbott Laboratories’ strong financial performance and strategic acquisition of Exact Sciences are significant positives, positioning the company for future growth. However, current technical indicators suggest bearish momentum, which could pose short-term challenges. The valuation is fair, and the earnings call highlights robust growth prospects despite some headwinds in specific markets.
To see Spark’s full report on ABT stock, click here.
More about Abbott Laboratories
Abbott Laboratories operates in the healthcare industry, focusing on the development and manufacturing of a wide range of medical devices, diagnostics, branded generic medicines, and nutritional products. The company is known for its commitment to advancing healthcare and improving patient outcomes globally.
Average Trading Volume: 6,235,449
Technical Sentiment Signal: Buy
Current Market Cap: $213.1B
See more insights into ABT stock on TipRanks’ Stock Analysis page.